Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.
Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser
Adryan Perez, Tianchen Li, Stephanie Hernandez, Renee Yilan Zhang and Chuanhai Cao
Alzheimer’s disease (AD) is a devastating neurodegenerative disease with no current cure. FDA approved drugs have been widely used to address symptoms of AD, but none have been successful in preventing or reversing its effects. As the prevalence of AD increases due to the increased lifespan of the population, it is becoming essential to discover new drugs or find alternative treatment approaches to overcome the potential toxicity induced by current medications. We have noted that coffee and melatonin can play a role in delaying disease onset and improving memory for AD patients. Once these independent discoveries were made, we tested the possibility of using them in combination as therapy for AD. In this review, we are going to summarize the results from various investigations testing caffeine, coffee, and melatonin and present a method for their combined use for maximum treatment efficacy against AD pathogenesis.